[Xinhua Pharmaceutical: Obtained Drug Registration Certificate for Ketorolac Trometamol Injection] On November 6, Xinhua Pharmaceutical (000756.SZ) announced that the company received the "Drug Registration Certificate" for Ketorolac Trometamol Injection approved and issued by the State Medical Products Administration. This drug is suitable for the short-term treatment of moderate to severe acute pain in adults who require opioid-level analgesia. It belongs to the category B of medical insurance. In 2025, the sales of this drug in China's public medical institutions will be approximately 230 million yuan. Obtaining the registration certificate this time will help enrich the company's analgesic product series and improve market competitiveness.